Production device of D-chiro-inositol

Abstract

The utility model discloses a D-chiro-inositol production device, and relates to the technical field of D-chiro-inositol production equipment, an inlet of a conversion tank is communicated with a substrate liquid tank and a whole-cell bacteria tank, an outlet of the conversion tank is communicated with a ceramic membrane device, a clear liquid outlet of the ceramic membrane device is communicated with a cation exchange resin column, and the cation exchange resin column is communicated with the whole-cell bacteria tank. An outlet of the cation exchange resin column is communicated with an anion exchange resin column, and an outlet of the anion exchange resin column is communicated with a desalting liquid tank; an outlet of the desalting liquid tank is communicated with a first concentration tank, an outlet of the first concentration tank is communicated with a simulated moving bed, a glucose phase outlet of the simulated moving bed is communicated with a glucose tank, and a D-chiro-inositol phase outlet of the simulated moving bed is communicated with a D-chiro-inositol tank through a pipeline. And the obtained D-chiro-inositol has high purity.

Description

Technical Field

[0001] The utility model relates to the technical field of D-chiroinositol production equipment, and particularly relates to a production device for D-chiroinositol. Background Art

[0002] D-chiroinositol is soluble in water and slightly soluble in organic solvents such as ethanol and methanol. It is one of the 9 isomers of inositol with optical activity and is also the bioactive isomer of vitamin B8. It exists in relatively high levels in plants such as buckwheat seeds and soybeans, as well as in some insects, mostly in the form of methylated or glycosylated derivatives, and is the biodegradation product of buckwheat sugar alcohol; it has the functions of insulin sensitization and promoting liver fat metabolism, can significantly reduce blood sugar content, and has a significant therapeutic effect on diabetes.

[0003] Chinese Patent CN109706189B discloses a preparation method of D-chiroinositol, which includes constructing an engineering bacterium expressing a thermostable muscle inositol dehydrogenase and / or a thermostable inositol monoketone isomerase gene, performing cell membrane permeability treatment and / or disruption on the engineering bacterium, and then converting muscle inositol into D-chiroinositol by using the permeable engineering bacterium or its lysate. At the same time, muscle inositol and D-chiroinositol are isomers, which causes difficulties in downstream separation and results in low purity. Summary of the Invention

[0004] The technical problem to be solved by the utility model is: aiming at the deficiencies existing in the prior art, to provide a production device for D-chiroinositol with high purity of D-chiroinositol.

[0005] To solve the above technical problem, the technical solution of the utility model is:

[0006] A production device for D-chiroinositol includes a conversion tank. The inlet of the conversion tank is respectively connected to a substrate liquid tank and a whole cell bacterium tank through pipelines. The outlet of the conversion tank is connected to a ceramic membrane device through a pipeline. The clear liquid outlet of the ceramic membrane device is connected to a cation exchange resin column through a pipeline. The outlet of the cation exchange resin column is connected to an anion exchange resin column through a pipeline. The outlet of the anion exchange resin column is connected to a desalting liquid tank through a pipeline;

[0007] The outlet of the desalting liquid tank is connected to a first concentration tank through a pipeline. The outlet of the first concentration tank is connected to a simulated moving bed through a pipeline. The glucose phase outlet of the simulated moving bed is connected to a glucose tank through a pipeline. The D-chiroinositol phase outlet of the simulated moving bed is connected to a D-chiroinositol tank through a pipeline.

[0008] As an improved technical solution, the clear liquid outlet of the ceramic membrane device is connected to an ultrafiltration membrane device through a pipeline, and the clear liquid outlet of the ultrafiltration membrane device is connected to the cation exchange resin column through a pipeline.

[0009] As an improved technical solution, the filtration pore size of the ceramic membrane device is 20 - 100 nm.

[0010] As an improved technical solution, the filtration pore size of the ultrafiltration membrane device is 1000 - 10000 Da.

[0011] As an improved technical solution, the outlet of the glucose tank is connected to the substrate liquid tank through a pipeline.

[0012] As an improved technical solution, the outlet of the D-chiro-inositol tank is connected to a second concentration tank through a pipeline, the outlet of the second concentration tank is connected to a crystallization tank through a pipeline, the outlet of the crystallization tank is connected to a dryer through a pipeline, and the outlet of the dryer is connected to a finished product tank.

[0013] As a preferred technical solution, the outlet of the second concentration tank is connected to a decolorization tank through a pipeline, the inlet of the decolorization tank is connected to an activated carbon tank, the outlet of the decolorization tank is connected to a filter through a pipeline, and the filtrate outlet of the filter is connected to the crystallization tank through a pipeline.

[0014] As a preferred technical solution, the outlet of the crystallization tank is connected to the second concentration tank through a pipeline.

[0015] Due to the adoption of the above technical solution, the beneficial effects of the present utility model are as follows:

[0016] A production device for D-chiro-inositol of the present utility model includes a conversion tank. The inlet of the conversion tank is respectively connected to a substrate liquid tank and a whole-cell bacteria tank through pipelines. The outlet of the conversion tank is connected to a ceramic membrane device through a pipeline. The clear liquid outlet of the ceramic membrane device is connected to a cation exchange resin column through a pipeline. The outlet of the cation exchange resin column is connected to an anion exchange resin column through a pipeline. The outlet of the anion exchange resin column is connected to a desalted liquid tank through a pipeline. The outlet of the desalted liquid tank is connected to a first concentration tank through a pipeline. The outlet of the first concentration tank is connected to a simulated moving bed through a pipeline. The glucose-phase outlet of the simulated moving bed is connected to a glucose tank through a pipeline. The D-chiro-inositol-phase outlet of the simulated moving bed is connected to a D-chiro-inositol tank through a pipeline. Exogenous genes including inositol-3-phosphate synthase (IPS), inositol monophosphatase (IMP), inositol dehydrogenase (IDH), and ketoisomerase gene are added to the substrate liquid containing glucose for transformation. The obtained transformation liquid is filtered by the ceramic membrane device, the clear liquid of the ceramic membrane is collected and enters the cation exchange resin column and the anion exchange resin column for desalting. The obtained desalted liquid is concentrated by the first concentration tank and then enters the simulated moving bed for separation to obtain a glucose phase and a D-chiro-inositol phase. The separation of the D-chiro-inositol phase and the substrate glucose is simple, and the obtained D-chiro-inositol has a high purity.

[0017] The clear liquid outlet of the ceramic membrane device of the present utility model is connected to an ultrafiltration membrane device through a pipeline, and the clear liquid outlet of the ultrafiltration membrane device is connected to the cation exchange resin column through a pipeline. The clear liquid of the ultrafiltration membrane can be used as the flushing water for the cation exchange resin column, saving resources and avoiding environmental pollution caused by direct discharge.

[0018] The filtration pore size of the ceramic membrane device is 20 - 100 nm, and the filtration pore size of the ultrafiltration membrane device is 1000 - 10000 Da, with good filtration and removal effects.

[0019] The outlet of the glucose tank is connected to the substrate liquid tank through a pipeline. By recycling the separated glucose phase back to the substrate liquid tank for conversion again, waste of raw materials is avoided and the yield of D-chiro-inositol is increased.

[0020] The outlet of the D-chiro-inositol tank is connected to a second concentration tank through a pipeline, the outlet of the second concentration tank is connected to a crystallization tank through a pipeline, the outlet of the crystallization tank is connected to a dryer through a pipeline, and the outlet of the dryer is connected to a finished product tank. The D-chiro-inositol phase separated by the simulated moving bed is concentrated, then crystallized and dried, and finally the finished D-chiro-inositol is obtained, improving the purity of the product.

[0021] The outlet of the second concentration tank is connected to a decolorization tank through a pipeline, the inlet of the decolorization tank is connected to an activated carbon tank, the outlet of the decolorization tank is connected to a filter through a pipeline, and the filtrate outlet of the filter is connected to the crystallization tank through a pipeline. By decolorization, the quality of the product is improved.

[0022] The outlet of the crystallization tank is connected to the second concentration tank through a pipeline. By recycling the crystallization mother liquor back to the second concentration tank, the yield of the product is increased, waste of raw materials is avoided, and costs are saved. Description of the Drawings

[0023] The present utility model will be further described below with reference to the drawings and embodiments.

[0024] Figure 1 It is a schematic structural diagram of an embodiment of the present utility model;

[0025] Wherein: 1, conversion tank; 2, substrate liquid tank; 3, whole cell bacteria tank; 4, ceramic membrane device; 5, cation exchange resin column; 6, anion exchange resin column; 7, desalted liquid tank; 8, first concentration tank; 9, simulated moving bed; 10, glucose tank; 11, D-chiro-inositol tank; 12, ultrafiltration membrane device; 13, second concentration tank; 14, crystallization tank; 15, dryer; 16, finished product tank; 17, decolorization tank; 18, activated carbon tank; 19, filter. Detailed implementation mode

[0026] The present utility model will be further described below in conjunction with the accompanying drawings and embodiments.

[0027] As Figure 1 shown, a production device for D-chiro-inositol includes a conversion tank 1. The inlet of the conversion tank 1 is respectively connected to a substrate liquid tank 2 and a whole-cell bacteria tank 3 through pipelines. The outlet of the conversion tank 1 is connected to a ceramic membrane device 4 through a pipeline. The clear liquid outlet of the ceramic membrane device 4 is connected to a cation exchange resin column 5 through a pipeline. The outlet of the cation exchange resin column 5 is connected to an anion exchange resin column 6 through a pipeline. The outlet of the anion exchange resin column 6 is connected to a desalting liquid tank 7 through a pipeline. The outlet of the desalting liquid tank 7 is connected to a first concentration tank 8 through a pipeline. The outlet of the first concentration tank 8 is connected to a simulated moving bed 9 through a pipeline. The glucose phase outlet of the simulated moving bed 9 is connected to a glucose tank 10 through a pipeline. The D-chiro-inositol phase outlet of the simulated moving bed 9 is connected to a D-chiro-inositol tank 11 through a pipeline. Exogenous genes including inositol-3-phosphate synthase (IPS), inositol monophosphatase (IMP), inositol dehydrogenase (IDH), and ketoisomerase gene are added to the substrate liquid containing glucose for conversion. The obtained conversion liquid is filtered by the ceramic membrane device 4, and the clear liquid of the ceramic membrane is collected and enters the cation exchange resin column 5 and the anion exchange resin column 6 for desalting. The obtained desalting liquid is concentrated by the first concentration tank 8 and then enters the simulated moving bed 9 for separation to obtain a glucose phase and a D-chiro-inositol phase. The separation of the D-chiro-inositol phase and the substrate glucose is simple, and the obtained D-chiro-inositol has a high purity.

[0028] The clear liquid outlet of the ceramic membrane device 4 is connected to an ultrafiltration membrane device 12 through a pipeline. The clear liquid outlet of the ultrafiltration membrane device 12 is connected to the cation exchange resin column 5 through a pipeline. The ultrafiltration membrane clear liquid can be used as the flushing water for the cation exchange resin column 5, saving resources and avoiding environmental pollution caused by direct discharge.

[0029] The filtration pore size of the ceramic membrane device 4 is 20 - 100 nm, and the filtration pore size of the ultrafiltration membrane device 12 is 1000 - 10000 Da, with good filtration and filtering effects.

[0030] The outlet of the glucose tank 10 is connected to the substrate liquid tank 2 through a pipeline. By recycling the separated glucose phase back to the substrate liquid tank 2 for re-conversion, waste of raw materials is avoided, and the yield of D-chiro-inositol is improved.

[0031] The outlet of the D-chiro-inositol tank 11 is connected to a second concentration tank 13 through a pipeline. The outlet of the second concentration tank 13 is connected to a crystallization tank 14 through a pipeline. The outlet of the crystallization tank 14 is connected to a dryer 15 through a pipeline. The outlet of the dryer 15 is connected to a finished product tank 16. The D-chiro-inositol phase separated by the simulated moving bed 9 is concentrated, then crystallized and dried, and finally the finished D-chiro-inositol is obtained, improving the purity of the product.

[0032] The outlet of the second concentration tank 13 is connected to a decolorization tank 17 through a pipeline. The inlet of the decolorization tank 17 is connected to an activated carbon tank 18. The outlet of the decolorization tank 17 is connected to a filter 19 through a pipeline. The filtrate outlet of the filter 19 is connected to the crystallization tank 14 through a pipeline. By decolorization, the quality of the product is improved.

[0033] The outlet of the crystallization tank 14 is connected to the second concentration tank 13 through a pipeline. By recycling the crystallization mother liquor back to the second concentration tank 13, the yield of the product is improved, avoiding waste of raw materials and saving costs.

[0034] It should be understood that these embodiments are only used to illustrate the present invention and not to limit the scope of the present invention. In addition, it should be understood that after reading the content taught by the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the appended claims of this application.

Claims

1. A production device for D-chiro-inositol, including a conversion tank, characterized in that: The inlet of the conversion tank is respectively connected to a substrate liquid tank and a whole-cell bacteria tank through pipelines. The outlet of the conversion tank is connected to a ceramic membrane device through a pipeline. The clear liquid outlet of the ceramic membrane device is connected to a cation exchange resin column through a pipeline. The outlet of the cation exchange resin column is connected to an anion exchange resin column through a pipeline. The outlet of the anion exchange resin column is connected to a desalting liquid tank through a pipeline. The outlet of the desalting liquid tank is connected to a first concentration tank through a pipeline. The outlet of the first concentration tank is connected to a simulated moving bed through a pipeline. The glucose-phase outlet of the simulated moving bed is connected to a glucose tank through a pipeline. The D-chiro-inositol-phase outlet of the simulated moving bed is connected to a D-chiro-inositol tank through a pipeline.

2. The production device of D-chiro-inositol according to claim 1, characterized in that: The clear liquid outlet of the ceramic membrane device is connected to an ultrafiltration membrane device through a pipeline. The clear liquid outlet of the ultrafiltration membrane device is connected to the cation exchange resin column through a pipeline.

3. The production device of D-chiro-inositol according to claim 1, characterized in that: The filtration pore size of the ceramic membrane device is 20 - 100 nm.

4. The production device of D-chiro-inositol according to claim 2, characterized in that: The filtration pore size of the ultrafiltration membrane device is 1000 - 10000 Da.

5. The production device of D-chiro-inositol according to claim 1, characterized in that: The outlet of the glucose tank is connected to the substrate liquid tank through a pipeline.

6. The production device of D-chiro-inositol according to claim 1, characterized in that: The outlet of the D-chiro-inositol tank is connected to a second concentration tank through a pipeline. The outlet of the second concentration tank is connected to a crystallization tank through a pipeline. The outlet of the crystallization tank is connected to a dryer through a pipeline. The outlet of the dryer is connected to a finished product tank.

7. The production device of D-chiro-inositol according to claim 6, characterized in that: The outlet of the second concentration tank is connected to a decolorization tank through a pipeline. The inlet of the decolorization tank is connected to an activated carbon tank. The outlet of the decolorization tank is connected to a filter through a pipeline. The filtrate outlet of the filter is connected to the crystallization tank through a pipeline.

8. The production device of D-chiro-inositol according to claim 6, characterized in that: The outlet of the crystallization tank is connected to the second concentration tank through a pipeline.

Images